Rapid Micro Biosystems (RPID) Expected to Announce Quarterly Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) is expected to issue its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect Rapid Micro Biosystems to post earnings of ($0.23) per share and revenue of $10.9330 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

Rapid Micro Biosystems Stock Performance

Shares of RPID opened at $3.97 on Friday. The firm has a market capitalization of $175.95 million, a PE ratio of -3.93 and a beta of 1.38. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The company has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $3.41. Rapid Micro Biosystems has a one year low of $1.86 and a one year high of $4.94.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.

Insider Activity

In other news, major shareholder Longitude Capital Partners Ii, sold 49,000 shares of Rapid Micro Biosystems stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $3.88, for a total transaction of $190,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert G. Jr. Spignesi sold 12,840 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $3.78, for a total value of $48,535.20. Following the completion of the sale, the chief executive officer owned 962,097 shares of the company’s stock, valued at $3,636,726.66. The trade was a 1.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 153,716 shares of company stock worth $635,998 over the last quarter. 29.96% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

A number of hedge funds have recently bought and sold shares of RPID. Vanguard Group Inc. boosted its position in shares of Rapid Micro Biosystems by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock worth $3,223,000 after purchasing an additional 60,655 shares during the period. Geode Capital Management LLC boosted its holdings in Rapid Micro Biosystems by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock valued at $631,000 after purchasing an additional 12,881 shares during the period. 683 Capital Management LLC purchased a new stake in Rapid Micro Biosystems during the 4th quarter worth about $350,000. Millennium Management LLC acquired a new stake in Rapid Micro Biosystems in the fourth quarter valued at approximately $338,000. Finally, Renaissance Technologies LLC lifted its position in shares of Rapid Micro Biosystems by 4.9% during the 4th quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after purchasing an additional 5,440 shares during the last quarter. Hedge funds and other institutional investors own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.